Delivery Order SPE2DB24D3014-SPE2DB25FKTCT

Award Date 4/8/25
Potential Completion Date 4/9/25
Potential Value $2.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,829.79, is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication. The contract has a firm fixed price pricing type and an ultimate completion date of February 28, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that...
This is a $2,877.84 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication, to support military healthcare programs. The contract has an ultimate completion date of April 8, 2025 and was awarded on April 7, 2025. AmerisourceBergen holds a significant $999,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,472.95 firm fixed-price contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a medical product, with a completion date of January 9, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,301.77, is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication. The contract has a firm fixed price pricing type and an ultimate completion date of October 20, 2023. This delivery order is issued under a larger Indefinite Delivery Contract (IDC) between...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,577.20 firm fixed-price contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication. The contract has an ultimate completion date of November 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $13,147.54, is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication. The contract has a period of performance through November 6, 2023 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger $999,999,999...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The contract, valued at $1,973.16, is for the delivery of ACTEMRA 162 MG/0.9 ML syringes to support military treatment programs and facilities. The contract has an ultimate completion date of April 10, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,721.76 firm fixed price contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication, with a completion date of November 29, 2024. The award is not associated with a set-aside program, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading pharmaceutical distribution company. The $2,630.88 order is for the supply of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty pharmaceutical product. This delivery order is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA valued at up to...
This is a delivery order award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication, with a ceiling value of $4,971.72 and a completion date of April 15, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract...
  • SPE2DB24D3014
    Indefinite Delivery Contract
  • SPE2DB24D3014-SPE2DB25FKTCT
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,607.81 firm-fixed-price contract is for the supply of ACTEMRA 162 MG/0.9 ML SYRINGE 0.9ML, a specialty medication, with a period of performance through April 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This order is not designated as a set-aside contract.

Generated 7/8/25, 2:25 PM